4D Molecular Therapeutics FDMT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.05M+21,664% | $85.09M+8,508,900% | $90K+2,900% | $15K+200% | $14K-50.0% | ||
| $64.98M+59.7% | $57.61M+33.7% | $49.44M+28.5% | $47.95M+50.5% | $40.7M+46.0% | ||
| $11.69M-9.7% | $12.77M-2.0% | $11.84M-6.4% | $11.52M+8.7% | $12.94M+25.7% | ||
| $76.67M+42.9% | $70.38M+25.4% | $61.28M+19.8% | $59.47M+40.1% | $53.64M+40.5% | ||
| $76.67M+42.9% | $70.38M+25.4% | $61.28M+19.8% | $59.47M+40.1% | $53.64M+40.5% | ||
| -$73.62M-37.3% | $0+100% | -$61.19M-19.7% | -$59.46M-40.0% | -$53.62M-40.6% | ||
| -2,416.1%+380,591pp | 0%+5,611,700pp | -67,983.3%+1,636,417pp | -396,373.3%+452,747pp | -383,007.1%-246,807pp | ||
| $4.86M-12.9% | $4.7M-27.3% | $4.33M-40.6% | $4.86M-35.6% | $5.58M-2.8% | ||
| $4.86M-14.0% | $4.68M-27.4% | $4.31M-40.9% | $4.8M-36.1% | $5.65M-1.5% | ||
| -$68.76M-43.3% | —— | -$56.88M-29.7% | -$54.66M-56.4% | -$47.97M-48.1% | ||
| -2,256.6%+340,400pp | —— | -63,195.6%+1,398,238pp | -364,386.7%+334,673pp | -342,657.1%-226,939pp | ||
| -$1.01-17.4% | —— | -$1.01-27.8% | -$0.98-55.6% | -$0.86-30.3% | ||
| -$1.01-17.4% | —— | -$1.01-27.8% | -$0.98-55.6% | -$0.86-30.3% | ||
| 68.1M+22.1% | 57.9M+7.4% | 56.1M+1.0% | 55.9M+1.2% | 55.7M+13.1% | ||
| 68.1M+22.1% | 57.9M+7.4% | 56.1M+1.0% | 55.9M+1.2% | 55.7M+13.1% | ||
| -$4K-106% | -$22K-4.8% | -$21K-2,000% | -$61K-35.6% | $67K+770% | ||
| $64.98M+59.7% | $57.61M+33.7% | $49.44M+28.5% | $47.95M+50.5% | $40.7M+46.0% | ||
| $3.05M+21,664% | $85.09M+8,508,900% | $90K+2,900% | $15K+200% | $14K-50.0% | ||
| -$73.62M-37.3% | $0+100% | -$61.19M-19.7% | -$59.46M-40.0% | -$53.62M-40.6% | ||
| -$72.35M-37.6% | $1.22M+102% | -$59.92M-20.0% | -$58.29M-41.3% | -$52.57M-42.2% | ||
| -$72.35M-37.6% | $1.22M+102% | -$59.92M-20.0% | -$58.29M-41.3% | -$52.57M-42.2% | ||
| -2,374.5%+373,126pp | 1.4%+5,502,101pp | -66,582.2%+1,598,151pp | -388,600%+436,640pp | -375,500%-243,489pp | ||
| -$73.62M-37.3% | $0+100% | -$61.19M-19.7% | -$59.46M-40.0% | -$53.62M-40.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is 4D Molecular Therapeutics's revenue?
- 4D Molecular Therapeutics (FDMT) generated $88.2M in revenue over the trailing twelve months, up 383560.9% year over year.
- Is 4D Molecular Therapeutics profitable?
- 4D Molecular Therapeutics is not currently profitable: it reported a net loss of $228.3M over the trailing twelve months, a -174314.2% net margin.
- What is 4D Molecular Therapeutics's earnings per share?
- 4D Molecular Therapeutics's diluted EPS over the trailing twelve months is $-3.86.
- Where does 4D Molecular Therapeutics's income statement data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
